Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
6.81
-0.01 (-0.15%)
Feb 21, 2025, 4:00 PM EST - Market closed
Astria Therapeutics Employees
Astria Therapeutics had 59 employees as of December 31, 2023. The number of employees increased by 17 or 40.48% compared to the previous year.
Employees
59
Change (1Y)
17
Growth (1Y)
40.48%
Revenue / Employee
n/a
Profits / Employee
-$1,695,661
Market Cap
384.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ATXS News
- 2 days ago - Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
- 5 days ago - Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
- 18 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 19 days ago - Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session - Business Wire
- 4 weeks ago - Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
- 5 weeks ago - Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
- 2 months ago - Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire